Azitra Inc (AZTR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Azitra Inc stock (AZTR) is currently trading at $0.27. Azitra Inc PE ratio is 0.01. Azitra Inc PS ratio (Price-to-Sales) is 239.97. Analyst consensus price target for AZTR is $4.50. WallStSmart rates AZTR as Sell.
- AZTR PE ratio analysis and historical PE chart
- AZTR PS ratio (Price-to-Sales) history and trend
- AZTR intrinsic value — DCF, Graham Number, EPV models
- AZTR stock price prediction 2025 2026 2027 2028 2029 2030
- AZTR fair value vs current price
- AZTR insider transactions and insider buying
- Is AZTR undervalued or overvalued?
- Azitra Inc financial analysis — revenue, earnings, cash flow
- AZTR Piotroski F-Score and Altman Z-Score
- AZTR analyst price target and Smart Rating
Azitra Inc
📊 No data available
Try selecting a different time range
AZTR Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Azitra Inc (AZTR)
AZTR trades at a significant discount to its Graham intrinsic value of $183.40, offering a 100% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Azitra Inc (AZTR) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Azitra Inc (AZTR) Key Strengths (1)
Trading at 1.18x book value, attractively priced
Supporting Valuation Data
Azitra Inc (AZTR) Areas to Watch (5)
Company is destroying shareholder value
Revenue declining -100.00%, a shrinking business
Very expensive at 240.0x annual revenue
Very low institutional interest at 1.71%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Azitra Inc (AZTR) Detailed Analysis Report
Overall Assessment
This company scores 16/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 1 register as strengths (avg 8.0/10) while 5 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (1.18) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Price/Sales. Some valuation metrics including Price/Sales (239.97) suggest expensive pricing. Growth concerns include Revenue Growth at -100.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -473.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -473.30% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -100.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AZTR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
AZTR's Price-to-Sales ratio of 239.97x trades 18% below its historical average of 290.95x (14th percentile). The current valuation is 45% below its historical high of 438.62x set in Feb 2026, and 26563% above its historical low of 0.9x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~438.6x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Azitra Inc (AZTR) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Azitra Inc operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -5M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Azitra Inc.
Bottom Line
Azitra Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 10:09:22 AM
About Azitra Inc(AZTR)
NYSE MKT
HEALTHCARE
BIOTECHNOLOGY
USA
Azitra Inc, a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. The company is headquartered in Branford, Connecticut.